Form D · Biotechnology

Visgenx, Inc.

San Diego, CA · CIK 0001783776

Offering snapshot reported Jun 14, 2023 · SEC filing

Reported sold
$2.76M
Offering amount: $3.5M
Investors reported
17
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 2, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 14, 2023Initial$2,763,915No comparison17SEC filing
Aug 17, 2020Amendment$5,747,283$822,020vs May 20, 202030SEC filing
May 20, 2020Initial$4,925,263No comparison27SEC filing
Jul 30, 2019Initial$655,000No comparison4SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-484208
Total Amount Sold includes amounts paid in both cash and pursuant to conversion of indebtedness.

Source: Form D, filed Jun 14, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Arthur Becker Director
Eric Carter, Ph.D., M.D. Director
Frank Douglas Director
Frank Douglas, M.D., Ph.D. Director
Martin Emanuele Director, Executive
Martin Emanuele, Ph.D. Director, Executive
Elaine Heron, Ph.D. Director
Thomas Meier, Ph.D., M.D. Director
William Pedranti Director, Executive
Santosh Vetticaden Director, Executive
Santosh Vetticaden, M.D., Ph.D., Mba Director, Executive
Santosh Vetticaden, Ph.D., M.D. Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
3210 Merryfield Row
San Diego, CA, 92121